AB0037 Complicated ra course with onset in elderly age

Autor: MM Ivanova, AM Satybaldyev, TF Akimova

Publikováno v: Speaker abstracts 2001.

Background Objectives Methods Disease course in 173 RA pts with onset in age older than 50 was analysed. It was demonstrated that in 101 pts (M:F = 12:89, median onset 58.6 y/o, median disease duration up to complication – 6.9 yrs, median age of la

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::419342fe62f977668d603cded0d4746a
https://doi.org/10.1136/annrheumdis-2001.1002

Neuronopathic Gaucher disease: Rare in the West, common in the East.

Autor: Goker-Alpan O; Lysosomal and Rare Disorder Research and Treatment Center, Fairfax, Virginia, USA., Ivanova MM; Lysosomal and Rare Disorder Research and Treatment Center, Fairfax, Virginia, USA.

Publikováno v: Journal of inherited metabolic disease [J Inherit Metab Dis] 2024 Sep; Vol. 47 (5), pp. 917-934. Date of Electronic Publication: 2024 May 20.

Biofabrication of an in-vitro bone model for Gaucher disease.

Autor: Banerjee D; Engineering Science and Mechanics Department, Penn State University, University Park, PA, United States of America.; Department of Medicine, Division of Cardiology, University of California, San Diego, La Jolla, CA, United States of America., Ivanova MM; Lysosomal & Rare Disorders Research & Treatment Center-LDRTC, Fairfax, VA, United States of America., Celik N; Engineering Science and Mechanics Department, Penn State University, University Park, PA, United States of America., Kim MH; Department of Biomedical Engineering, Pennsylvania State University, University Park, PA, United States of America., Derman ID; Engineering Science and Mechanics Department, Penn State University, University Park, PA, United States of America., Limgala RP; Lysosomal & Rare Disorders Research & Treatment Center-LDRTC, Fairfax, VA, United States of America., Ozbolat IT; Engineering Science and Mechanics Department, Penn State University, University Park, PA, United States of America.; Department of Biomedical Engineering, Pennsylvania State University, University Park, PA, United States of America.; The Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA, United States of America.; Materials Research Institute, Pennsylvania State University, University Park, PA, United States of America.; Department of Neurosurgery, Pennsylvania State College of Medicine, Hershey, PA, United States of America.; Medical Oncology, Cukurova University, Adana, Turkey.; Biotechnology Research and Application Center, Cukurova University, Adana, Turkey., Goker-Alpan O; Lysosomal & Rare Disorders Research & Treatment Center-LDRTC, Fairfax, VA, United States of America.

Publikováno v: Biofabrication [Biofabrication] 2023 Sep 22; Vol. 15 (4). Date of Electronic Publication: 2023 Sep 22.

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease.

Autor: Ivanova MM; Translational Research, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States., Dao J; Translational Research, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States., Kasaci N; Translational Research, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States., Friedman A; Translational Research, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States., Noll L; Translational Research, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States., Goker-Alpan O; Translational Research, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States.

Publikováno v: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2022 Nov 24; Vol. 13, pp. 1029130. Date of Electronic Publication: 2022 Nov 24 (Print Publication: 2022).

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.

Autor: Ivanova MM; Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States of America., Dao J; Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States of America., Kasaci N; Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States of America., Adewale B; Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States of America., Nazari S; Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States of America., Noll L; Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States of America., Fikry J; Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States of America., Sanati AH; Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States of America., Goker-Alpan O; Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, United States of America.

Publikováno v: PloS one [PLoS One] 2021 Oct 25; Vol. 16 (10), pp. e0247211. Date of Electronic Publication: 2021 Oct 25 (Print Publication: 2021).